Analysts forecast that Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Rating) will report $700,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Oncternal Therapeutics’ earnings. The highest sales estimate is $1.20 million and the lowest is $250,000.00. Oncternal Therapeutics posted sales of $750,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 6.7%. The firm is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Oncternal Therapeutics will report full-year sales of $2.50 million for the current fiscal year, with estimates ranging from $1.00 million to $4.80 million. For the next financial year, analysts expect that the company will post sales of $1.13 million, with estimates ranging from $1.00 million to $1.25 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Oncternal Therapeutics.
Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.09. Oncternal Therapeutics had a negative net margin of 726.14% and a negative return on equity of 31.86%. During the same quarter in the previous year, the company earned ($0.09) earnings per share.
Shares of Oncternal Therapeutics stock opened at $1.15 on Monday. Oncternal Therapeutics has a 12-month low of $1.11 and a 12-month high of $6.89. The stock has a market cap of $56.84 million, a PE ratio of -1.83 and a beta of 1.67. The company has a 50-day moving average of $1.60 and a two-hundred day moving average of $2.49.
In related news, CEO James B. Breitmeyer acquired 25,000 shares of the company’s stock in a transaction that occurred on Thursday, January 27th. The stock was purchased at an average price of $1.68 per share, for a total transaction of $42,000.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. In the last ninety days, insiders have purchased 46,003 shares of company stock worth $78,134. Corporate insiders own 4.00% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Morgan Stanley increased its stake in Oncternal Therapeutics by 486.6% in the second quarter. Morgan Stanley now owns 274,481 shares of the company’s stock valued at $1,304,000 after purchasing an additional 227,688 shares during the last quarter. Bank of America Corp DE increased its stake in Oncternal Therapeutics by 175.2% in the second quarter. Bank of America Corp DE now owns 55,306 shares of the company’s stock valued at $263,000 after purchasing an additional 35,206 shares during the last quarter. Wells Fargo & Company MN increased its stake in Oncternal Therapeutics by 1,472.5% in the second quarter. Wells Fargo & Company MN now owns 98,676 shares of the company’s stock valued at $469,000 after purchasing an additional 92,401 shares during the last quarter. SG Americas Securities LLC increased its stake in Oncternal Therapeutics by 74.4% in the third quarter. SG Americas Securities LLC now owns 26,617 shares of the company’s stock valued at $111,000 after purchasing an additional 11,351 shares during the last quarter. Finally, Advisor Group Holdings Inc. increased its stake in Oncternal Therapeutics by 10.3% in the third quarter. Advisor Group Holdings Inc. now owns 28,081 shares of the company’s stock valued at $117,000 after purchasing an additional 2,631 shares during the last quarter. 27.14% of the stock is owned by hedge funds and other institutional investors.
About Oncternal Therapeutics (Get Rating)
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins.
- Get a free copy of the StockNews.com research report on Oncternal Therapeutics (ONCT)
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.